Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Sep 30, 2021
Revenue for the three and nine months ended September 30, 2021 was $1.2 million and $4.7 million, respectively, compared to $1.2 million and $2.5 million for the same periods in 2020.
As of September 30, 2021, Adaptimmune had cash and cash equivalents of $42.9 million and Total Liquidity1 of $240.1 million.
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
For Fiscal Year Ending Dec 31, 2020
For complete information regarding our financials, see our periodic filings